Tolerx
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
300 Technology Sq Ste 3, Cambridge, Mass...Phone Number
(617) 354-8100Website
www.tolerx.comRevenue
$23.6 MillionIndustry
ZI Rank: 1
About Tolerx
Tolerx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tolerx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Tolerx
Funding: Get notified immidiatlly once Tolerx has new funding data
Product Launch: Get notified when Tolerx launches new products
Tolerx, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Tolerx is spiking on competitors!
Earning: See what the market has to say on Tolerx recently announced quarterly report
Check if Tolerx has recently received funding, and reach out quickly before it becomes old news!
Click to see if Tolerx had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Tolerx
Find more new buyers
Company Profile Activity
Activity Insights
Tolerx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Tolerx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Tolerx.
Tolerx Tech Stack
A closer look at the technologies used by Tolerx
Top Manufacturing Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tolerx
Tolerx, Inc., a world leader in the understanding of T cell function, is developing novel therapies intended to treat autoimmune diseases, diabetes, and cancer by specifically modulating T cell activity. company's pipeline includes its lead candidate, otelixizumab, a targeted T cell immunomodulator in Phase 3 development for the treatment of type 1... Read More
